RT001

Phase 3Small molecule

RRevance Therapeutics, Inc.

RT001 is one of 84 small molecule programs targeting Progressive Supranuclear Palsy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Progressive Supranuclear PalsyActive, not recruiting

Amyotrophic Lateral SclerosisActive, not recruiting

AtaxiaActive, not recruiting

Progressive Supranuclear PalsyPhase 2

Active, not recruiting

Amyotrophic Lateral SclerosisPhase 2

Active, not recruiting

AtaxiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

220 competitors in Amyotrophic Lateral Sclerosis

#DrugCompanyPhaseTrials

Tivicay

GSK

Phase 3

2 2

Radicava

Shionogi

Phase 3

2 3

Simdax

Orion Corporation, Orion Pharma

Phase 3

1 4

Ultomiris

Robitussin

Lithobid

SSolvay Pharmaceuticals

Phase 3

3 7

Minocin

TTriax

Phase 3

2 8

Sodium Valproate

AstraZeneca

Phase 3

1 9

BOTULINUM TOXIN TYPE B

Eisai

Phase 3

1 10

Nolvadex

AstraZeneca

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lateral Canthal Lines5 trials

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

Completed·RRevance Therapeutics, Inc.·Phase 2·NCT00907387·72 enrolled

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

Completed·RRevance Therapeutics, Inc.·Phase 2·NCT00884234·30 enrolled

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

Completed·RRevance Therapeutics, Inc.·Phase 2·NCT00888914·60 enrolled

Show 2 more trials

A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

Completed·RRevance Therapeutics, Inc.·Phase 2·NCT01124552·180 enrolled

Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

Completed·RRevance Therapeutics, Inc.·Phase 2·NCT01124565·40 enrolled

Progressive Supranuclear Palsy1 trial

RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY

Unknown status·BBiojiva LLC·Phase 2·NCT04937530·40 enrolled

Efficacy and Safety1 trial

A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy

Active, not recruiting·BBiojiva LLC·Phase 2/3·NCT03570931·19 enrolled

Ataxia1 trial

A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia

Completed·BBiojiva LLC·Phase 3·NCT04102501·65 enrolled

Amyotrophic Lateral Sclerosis1 trial

RT001 in Amyotrophic Lateral Sclerosis

Completed·BBiojiva LLC·Phase 2·NCT04762589·43 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for RT001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RT001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RT001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Revance Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: RRevance Therapeutics, Inc.

RT001

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lateral Canthal Lines5 trials

Progressive Supranuclear Palsy1 trial

Efficacy and Safety1 trial

Ataxia1 trial

Amyotrophic Lateral Sclerosis1 trial

References

Drug Info

Quick Facts

Related News